Feedback / Questions
Lynparza (olaparib) - Merck (MSD), AstraZeneca
Lynparza: "Median OS improved by 12.9 months with maintenance Lynparza over placebo (p-value: 0.0537)"; Ovarian cancer
(AstraZeneca)
-
Jun 2, 2020 -
ASCO 2020
P3 data
•
Oncology • Ovarian Cancer
https://www.astrazeneca.com/content/dam/az/Investor_Relations/events/20200601%20VBO3%20SG,%20GR%20-%20IR%20Nick.pdf
Jun 2, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious